---
category: news
title: "Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors & Blood Cancers through Agreement with Califia Pharma"
excerpt: "PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence (\"A.I.\") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics,"
publishedDateTime: 2021-01-04T06:00:00Z
originalUrl: "https://www.morningstar.com/news/pr-newswire/20210104da36411/lantern-pharma-announces-launch-of-antibody-drug-conjugate-adc-program-to-target-solid-tumors-blood-cancers-through-agreement-with-califia-pharma"
webUrl: "https://www.morningstar.com/news/pr-newswire/20210104da36411/lantern-pharma-announces-launch-of-antibody-drug-conjugate-adc-program-to-target-solid-tumors-blood-cancers-through-agreement-with-califia-pharma"
type: article
quality: 0
heat: 0
published: false

provider:
  name: Morningstar, Inc.
  domain: morningstar.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg"
    width: 400
    height: 296
    isCached: true

secured: "PXlOt73WvF5m0kUgONlRHihKrD76a26a/xihX1fG6bGQf63kSGoImKb6eBi4ZuKiquXzSoN2J4KHLrpQlrMXkO6tfhB8hT93wT79i42lafsRu+79X4x36eZh8inbVR0wc+UJzAE9VPqdBA0Sd2iW33cu3q44CKVou1KwfWmKPBbyUE22oIlb85PhbgkHZF8A9rfG7mxbCLZ/YzwvzCEgP3lxjCIPPOriNku+uqCqjjOJa9Msv98ZFzx2yuywrYadGLbBY/uvHcSfezfzswc+5RK3i/ubcDx7zeYYZp5Chk9lDOHzr/+wsShmYOaPMYmvKt8cVeikyF9C+NcAH8JNx63Hca3V2L8y63W3JF9tpYA=;g5ajI/LvtnpAnbuILLB6Gw=="
---

